Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Experimental | receiving drug dose of 5mg |
|
| Group 2 | Active Comparator | receiving grug dose of 10 mg |
|
| Group 3 | Active Comparator | receiving dose of 20 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rosuvastatin | Drug | a dose of 5mg were given and were compared for the cpk, ast and ldl levels |
| |
| Measure | Description | Time Frame |
|---|---|---|
| impact of rosuvstatin over LDL, CPK and AST levels | Pre- and post intervention levels of fasting serum low-density lipoprotein (LDL) in mg/dL were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin. | 12 weeks |
| impact of rosuvstatin over LDL, CPK and AST levels | Pre- and post-intervention levels of creatine phosphokinase (CPK) in mcg/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of rhabdomyolysis. | 12 weeks |
| impact of rosuvstatin over LDL, CPK and AST levels | Pre- and post-intervention levels of Aspartate Aminotransferase (AST) in U/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of liver damage. | 12 weeks |
Not provided
Not provided
Inclusion Criteria:
patients who were already on statins
Exclusion Criteria:
hereditary diseases including familial hypercholesterolemia and kidney diseases
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sikandar | Central Park Medical College | Principal Investigator |
| Sikandar | Central Park Medical College & Teaching Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Park Teaching Hospital | Lahore | 54600 | Pakistan |
Not provided
| ID | Term |
|---|---|
| D006938 | Hyperlipoproteinemia Type II |
| ID | Term |
|---|---|
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068718 | Rosuvastatin Calcium |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rosuvastatin |
| Drug |
a dose of 10 mg were given and were compared for the cpk, ast and ldl levels |
|
| Rosuvastatin | Drug | a dose of 20 mg were given and were compared for the cpk, ast and ldl levels |
|
| D006951 | Hyperlipoproteinemias |
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006845 |
| Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |